These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 20529245)

  • 1. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
    Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
    J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
    Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
    Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
    Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Dörken B; Pezzutto A; Westermann J
    J Gene Med; 2012 Feb; 14(2):128-37. PubMed ID: 22228591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
    Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
    J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.
    Zhou Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6711-6718. PubMed ID: 36692548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
    Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
    J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
    Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
    Clifton GT; Litton JK; Arrington K; Ponniah S; Ibrahim NK; Gall V; Alatrash G; Peoples GE; Mittendorf EA
    Ann Surg Oncol; 2017 Aug; 24(8):2161-2167. PubMed ID: 28315060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
    J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel.
    Kageyama S; Kitano S; Hirayama M; Nagata Y; Imai H; Shiraishi T; Akiyoshi K; Scott AM; Murphy R; Hoffman EW; Old LJ; Katayama N; Shiku H
    Cancer Sci; 2008 Mar; 99(3):601-7. PubMed ID: 18081877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
    Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
    Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
    Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
    Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
    Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.